RxDoctor Payments Data

Briana Dahl

Family · Maryville, TNNPI 1477217487

Payments from drug & device makers

$8,504in general payments, 2019–2025

Across 351 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Novartis$1K
  • Johnson & Johnson$623
  • Edwards Lifesciences$610
  • Amgen$579
  • Boehringer Ingelheim$489
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$8,40899%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,504 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$48,158
Medicare patients
313
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban334$396,279
EntrestoSacubitril/Valsartan107$117,564
Repatha SureclickEvolocumab57$57,144
JardianceEmpagliflozin52$52,906
XareltoRivaroxaban53$42,275
FarxigaDapagliflozin Propanediol36$23,532
Praluent PenAlirocumab13$10,078
Valsartan240$9,636
BrilintaTicagrelor11$8,202
Metoprolol Succinate526$7,021
Flecainide Acetate108$4,264
Atorvastatin Calcium283$2,960
Carvedilol295$2,551
Nebivolol Hcl46$2,136
Rosuvastatin Calcium212$2,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$396$396,279334 claims
NovartisEntresto$1,010$117,564107 claims
Boehringer IngelheimJardiance$489$52,90652 claims
Johnson & JohnsonXarelto$623$42,27553 claims
AstraZenecaFarxiga, Brilinta$428$31,73447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →